The expression levels of SLC12A5 were also positively correlated with higher Gleason score (Fig. 1F), advanced TNM stage (large tumor size, lymph node spread, distant metastases) and higher PSA levels in TCGA dataset (Supplementary Fig. S1A–D), suggesting a potential oncogenic role of SLC12A5 in prostate cancer progression. This evidence concerns the gene SLC12A5 and prostate carcinoma.